Wang Yida, Zhang Feng, Qian Zhiwen, Jiang Ying, Wu Danping, Liu Lu, Ning Xin, Mei Jie, Chen Daozhen, Zhang Yan
Department of Oncology, Wuxi Maternal and Child Health Care Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214002, China.
Department of Oncology, Wuxi Maternity and Child Health Care Hospital, Women's Hospital of Jiangnan University, Jiangnan University, Wuxi, 214002, China.
Exp Hematol Oncol. 2025 Jul 29;14(1):101. doi: 10.1186/s40164-025-00691-y.
Collagen in the tumor microenvironment plays diverse biological roles, from serving as the structural framework of tumors to influencing immune responses, angiogenesis, and tumor progression. Consequently, developing strategies to optimize the suppression of collagen's promotive effects on tumor growth while maintaining its inhibitory functions on tumor initiation has become a key focus of cancer research and therapy. A significant challenge remains in identifying a biomarker with both high sensitivity and specificity for cancer diagnosis. This review, therefore, highlights the substantial value and clinical relevance of collagen as a biomarker throughout cancer onset and progression. It explores the fundamental link between collagen and immunotherapeutic outcomes, further illustrating how targeting collagen-along with its interactions with tumors and immune cells-can offer more reliable predictive markers for personalized immunotherapy. This approach ultimately enables the development of more tailored and standardized treatment regimens for patients with cancer.
肿瘤微环境中的胶原蛋白发挥着多种生物学作用，从作为肿瘤的结构框架到影响免疫反应、血管生成和肿瘤进展。因此，开发策略以优化对胶原蛋白促进肿瘤生长作用的抑制，同时维持其对肿瘤起始的抑制功能，已成为癌症研究和治疗的关键重点。在识别对癌症诊断具有高灵敏度和特异性的生物标志物方面，仍然存在重大挑战。因此，本综述强调了胶原蛋白作为生物标志物在整个癌症发生和进展过程中的重要价值和临床相关性。它探讨了胶原蛋白与免疫治疗结果之间的基本联系，进一步说明了靶向胶原蛋白及其与肿瘤和免疫细胞的相互作用如何能够为个性化免疫治疗提供更可靠的预测标志物。这种方法最终能够为癌症患者制定更具针对性和标准化的治疗方案。
